Johnson & Johnson
263.81USD
-3.8000 (-1.42%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on JNJ.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $2.92▼ | $3.01 | 0 | 2 |
| Next quarter | $2.68▼ | $2.93 | 0 | 1 |
| Current year | $11.12▼ | $11.66 | 0 | 2 |
| Next year | $11.62▼ | $12.83 | 0 | 2 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-09-30 | $2.52 | $2.59 | +0.07 (+2.7%) |
| 2026-06-30 | $2.85 | $2.9 | +0.05 (+1.6%) |
| 2026-03-31 | $2.68 | $2.7 | +0.02 (+0.8%) |
| 2025-12-31 | $2.46 | $2.46 | -0.00 (-0.1%) |
390 ratings from 36 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Wells Fargo | Maintained | Overweight | $275 $287 | Oct 16, 2026 |
| Morgan Stanley | Maintained | Overweight | $294 $292 | Oct 15, 2026 |
| Leerink Partners | Maintained | Outperform | $276 $272 | Oct 14, 2026 |
| Wells Fargo | Maintained | Overweight | $282 $275 | Oct 14, 2026 |
| RBC Capital | Maintained | Outperform | $290 $280 | Oct 14, 2026 |
| Guggenheim | Reiterated | Buy | $287 | Oct 7, 2026 |
| RBC Capital | Maintained | Outperform | $287 $290 | Oct 6, 2026 |
| Citigroup | Maintained | Buy | $298 $303 | Oct 5, 2026 |
| JP Morgan | Maintained | Neutral | $270 $285 | Sep 29, 2026 |
| HSBC | Maintained | Buy | $290 $320 | Sep 10, 2026 |
| UBS | Maintained | Buy | $280 $320 | Sep 2, 2026 |
| Guggenheim | Maintained | Buy | $270 $287 | Aug 6, 2026 |
| Wells Fargo | Maintained | Overweight | $272 $282 | Aug 3, 2026 |
| Guggenheim | Reiterated | Buy | $270 | Jul 17, 2026 |
| Raymond James | Maintained | Outperform | $258 $265 | Jul 16, 2026 |
| RBC Capital | Reiterated | Outperform | $287 | Jul 16, 2026 |
| Wells Fargo | Maintained | Overweight | $263 $272 | Jul 16, 2026 |
| Morgan Stanley | Maintained | Overweight | $284 $294 | Jul 16, 2026 |
| TD Cowen | Maintained | Buy | $250 $300 | Jul 13, 2026 |
| RBC Capital | Maintained | Outperform | $265 $287 | Jul 13, 2026 |
| B of A Securities | Maintained | Neutral | $254 $263 | Jul 10, 2026 |
| Morgan Stanley | Maintained | Overweight | $283 $284 | Jul 8, 2026 |
| Citigroup | Maintained | Buy | $285 $298 | Jul 8, 2026 |
| Guggenheim | Maintained | Buy | $266 $270 | Jun 26, 2026 |
| Leerink Partners | Upgraded from Market Perform | Outperform | $265 | May 13, 2026 |
82 filings from 17 insiders · 7 buy / 7 sell over 6m
Officers and directors of JNJ, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Pinto Daniel EDirector | GrantDeferred Share Units | 113.098 | $276.31 | $31k | Sep 8, 2026 |
| Woods Eugene A.Director | GrantDeferred Share Units | 135.717 | $276.31 | $37k | Sep 8, 2026 |
| HEWSON MARILLYN ADirector | GrantDeferred Share Units | 180.956 | $276.31 | $50k | Sep 8, 2026 |
| Schmid TimothyOfficer, EVP, WW Chair, MedTech | Exercise | 11.1k | $131.94 | $1.46M | Sep 2, 2026 |
| Schmid TimothyOfficer, EVP, WW Chair, MedTech | Sell | 11.1k | $274.74 | $3.04M | Sep 2, 2026 |
| Schmid TimothyOfficer, EVP, WW Chair, MedTech | Exercise | 22.5k | $151.41 | $3.41M | Sep 2, 2026 |
| Schmid TimothyOfficer, EVP, WW Chair, MedTech | Sell | 22.5k | $274.74 | $6.19M | Sep 2, 2026 |
| Schmid TimothyOfficer, EVP, WW Chair, MedTech | ExerciseEmployee Stock Options (Right to Buy) | 11.1k | — | — | Sep 2, 2026 |
| Schmid TimothyOfficer, EVP, WW Chair, MedTech | ExerciseEmployee Stock Options (Right to Buy) | 22.5k | — | — | Sep 2, 2026 |
| TAUBERT JENNIFER LOfficer | Exercise | 15.0k | $115.67 | $1.74M | Aug 17, 2026 |
| TAUBERT JENNIFER LOfficer | Sell | 15.0k | $263.36 | $3.95M | Aug 17, 2026 |
| DUATO JOAQUIN BOIXChief Executive Officer | Exercise | 123.3k | $115.67 | $14.26M | Aug 13, 2026 |
| DUATO JOAQUIN BOIXChief Executive Officer | Sell | 123.3k | $261.00 | $32.20M | Aug 13, 2026 |
| FORMINARD ELIZABETHOfficer | Exercise | 9.3k | $131.94 | $1.23M | Aug 6, 2026 |
| FORMINARD ELIZABETHOfficer | Sell | 15.9k | $255.93 | $4.09M | Aug 6, 2026 |
| DUATO JOAQUIN BOIXChief Executive Officer | Sell | 48.5k | $258.06 | $12.52M | Aug 5, 2026 |
| BROADHURST VANESSAOfficer | Exercise | 23.1k | $129.51 | $3.01M | Jul 20, 2026 |
| BROADHURST VANESSAOfficer | Sell | 23.1k | $251.27 | $5.79M | Jul 20, 2026 |
| WENGEL KATHRYN EChief Technology Officer | Exercise | 10.0k | $115.67 | $1.16M | Jun 11, 2026 |
| WENGEL KATHRYN EChief Technology Officer | Sell | 10.0k | $241.15 | $2.41M | Jun 11, 2026 |
No analyst notes on JNJ yet.
Analyst Ratings
22 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 5 | 11 | 6 | 1 | 0 | Buy2.13 |
| 1 mo ago | 5 | 11 | 6 | 1 | 0 | Buy2.13 |
| 2 mo ago | 5 | 11 | 6 | 1 | 0 | Buy2.13 |
| 3 mo ago | 5 | 11 | 6 | 1 | 0 | Buy2.13 |
Members whose judged calls on JNJ have played out most reliably.
No settled calls on JNJ yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice